Accendra Health, Inc. (ACCH)
| Market Cap | 1.57M -99.3% |
| Revenue (ttm) | 2.55B -7.1% |
| Net Income | -171.56M |
| EPS | -2.24 |
| Shares Out | 76.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,678,176 |
| Open | 0.0225 |
| Previous Close | 0.0195 |
| Day's Range | 0.0190 - 0.0225 |
| 52-Week Range | 0.0111 - 4.6890 |
| Beta | 1.62 |
| Analysts | Sell |
| Price Target | 1.40 (+6,762.75%) |
| Est. Earnings | Feb 19, 2027 |
About Accendra Health
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines includi... [Read more]
Financial Performance
In 2025, Accendra Health's revenue was $2.76 billion, an increase of 3.06% compared to the previous year's $2.68 billion. Losses were -$1.10 billion, 203.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ACCH stock is "Sell." The 12-month stock price target is $1.40, which is an increase of 6,762.75% from the latest price.
News
Accendra Health Receives Delisting Notice From the New York Stock Exchange
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it received notification from the New York Stock Exchange (“NYSE”) on November 16, 2026, informin...
BLUE SHIELD OF CALIFORNIA EXPANDS COLLABORATION WITH ACCENDRA HEALTH TO IMPROVE ACCESS TO HOME-BASED CARE
OAKLAND, Calif., Nov. 16, 2026 /PRNewswire/ -- Blue Shield of California today announced an expanded collaboration with Accendra Health brands, including Apria and Byram, that integrates durable medic...
NYSE to Commence Delisting Proceedings Against Accendra Health, Inc. (ACH)
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock — ti...
Accendra Health Earnings Call Transcript: Q3 2026
Q3 results missed expectations, with adjusted EBITDA of $47.8 million and revenue down 1% excluding specified impacts. A turnaround targets referral growth, patient retention, collections, and cost efficiency; FY 2026 adjusted EBITDA is now expected up to 30% below prior guidance midpoint.
Accendra Health Slides: Q3 2026
Accendra Health has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Accendra Health Earnings release: Q3 2026
Accendra Health released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Accendra Health Quarterly report: Q3 2026
Accendra Health has published its Q3 2026 quarterly earnings report on November 5, 2026.
Accendra Health Reports Third Quarter 2026 Financial Results
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the third quarter ended September 30, 2026. Unless otherwise noted, the results her...
Accendra Health Announces Extension of $150 Million Receivables Sale Program To 2029
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it executed an amendment to its Receivables Purchase Agreement (the “Receivables Sale Program”) o...
Accendra Health Receives Continued Listing Standard Notice from NYSE Regarding Market Capitalization and Stockholders' Equity; Intends to Submit Business Plan and Return to Compliance with NYSE Listing Standard
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 27, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYS...
Accendra Health Proxy statement: Proxy filing
Accendra Health filed a proxy statement on October 29, 2026, providing details for shareholder voting and corporate governance matters.
Accendra Health Announces Third Quarter 2026 Earnings Release Date and Conference Call
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the third quarter of 2026 on Thursday, November 5, 2026, after trading ends on ...
Accendra Health Proxy statement: Proxy filing
Accendra Health filed a proxy statement on October 19, 2026, providing details for shareholder voting and corporate governance matters.
Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 6, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE...
Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company's Next Chapter of Growth
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today named Kenneth Gardner-Smith as the Company's next President and Chief Executive Officer. Gardner-Smith, who has ...
Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health (the “Company”) is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer. Given recent...
Accendra Health Earnings Call Transcript: Q2 2026
Second quarter results missed expectations due to revenue growth and collection rate challenges, but operational improvements, cost reductions, and new commercial agreements are expected to drive stronger performance in late 2026 and 2027. Debt was reduced by $400 million, and free cash flow is projected to be break-even for 2026.
Accendra Health Slides: Q2 2026
Accendra Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 10, 2026.
Accendra Health Earnings release: Q2 2026
Accendra Health released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Accendra Health Quarterly report: Q2 2026
Accendra Health has published its Q2 2026 quarterly earnings report on August 10, 2026.
Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) announced today that its Board of Directors adopted a Section 382 Rights Agreement (the “Tax Asset Preservation Plan”) d...
Accendra Health Reports Second Quarter 2026 Financial Results
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the second quarter ended June 30, 2026. Unless otherwise noted, the results herein ...
Accendra Health's Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that President and Chief Executive Officer Edward A. Pesicka has informed the Board of Directors of his ...
Accendra Health Announces Second Quarter 2026 Earnings Release Date and Conference Call
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the second quarter of 2026 on Monday, August 10, 2026, before trading begins on...
Accendra Health Registration statement: Registration filing
Accendra Health filed a registration statement on July 15, 2026, providing details about a securities offering with the SEC.